Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Observational 4Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 394Multiple Endocrine Neoplasia Type 1 156Carcinoma, Neuroendocrine 123Thyroid Cancer, Papillary 118Pituitary Neoplasms 116Thyroid Neoplasms 100Pheochromocytoma 91Neoplasms 79Carcinoid Tumor 76Thyroid Carcinoma, Anaplastic 73Adrenocortical Carcinoma 73Paraganglioma 65Neoplasm Metastasis 56Adenocarcinoma, Follicular 53Carcinoma, Non-Small-Cell Lung 51Carcinoma, Medullary 50Insulinoma 49Pancreatic Neoplasms 47Adenoma, Islet Cell 47Colorectal Neoplasms 44Breast Neoplasms 44Small Cell Lung Carcinoma 42Sarcoma 42Gastro-enteropancreatic neuroendocrine tumor 42Carcinoma, Renal Cell 41Somatostatinoma 38Head and Neck Neoplasms 38Melanoma 37Lung Neoplasms 37Adrenal Gland Neoplasms 34

Interventions

3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carney Complex × Endocrine × Clear all
NCT01560260 2018-09-21

Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

National Cancer Institute (NCI)

Phase 2 Completed
20 enrolled 15 charts
CNSEndocrineGastrointestinalSarcoma

Chondrosarcoma, Paraganglioma, Gastrointestinal Stromal Tumors, Carney Complex

Data powered by HemOnc (CC BY 4.0) Colophon âš¡